|Synonyms||GS-9820; GS9820; GS 9820; CAL-120; CAL 120; CAL120; Acalisib; UNII-OVW60IDW1D.|
|Description||Acalisib, also known as GS-9820, is an inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. p110beta/delta PI3K inhibitor GS-9820 inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.|
|Current Developer||Gilead Sciences|
RP-6530, a purine derivative, has been found to be a PI3Kδ/γ inhibitor that could exhibit cytotoxicity in some lymphoma primary cells so that is significant in ...
PI3Ky inhibitor 1
PI3Ky inhibitor 1 is a potent PI3Ky inhibitor.
SAR-405 is a potent and selective inhibitor of phosphoinositide 3-kinase (PI3K) class III isoform Vps34 (IC50= 1.2 nM, Kd= 1.5 nM) without disrupting other PI3K...
Taselisib, also known as GDC0032 or RG7606, is a selective, potent, orally bioavailable inhibitor of PI3Ka with a Ki = 0.2nM, and with reduced inhibitory activi...
This active molecular is the S-configuration isomer of AZD6482. AZD6482 is a selective, ATP competitive PI3Kβ inhibitor and IC50 value is 0.01 μm. Meanwhile, AZ...
AZD-8835 was selected as a clinical candidate for the treatment of PIK3CA-dependent cancers and is currently in phase I clinical trials. It is an orally bioavai...
TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit. Recent studies showed that TGX-221 has antiproliferat...
NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.
CNX-1351 is a selective covalent Inhibitor of PI3Kα. In an end point assay, CNX-1351 potently inhibited PI3Kα and was 20−400 times less potent against β, γ, an...
GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineopla...
BKM120, also called as buparlisib or NVP-BKM120, activity in a range of preclinical cancermodels, specifically inhbits class I PI3K isoforms, which blocks p110α...
CAY10505 is a phosphatidylinositol 3-kinase-γ inhibitor, was found to significantly improve acetylcholine-induced endothelium dependent relaxation, serum nitrat...
AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ. Phase 1.
LY3023414, a quinoline derivative, has been found to be a PI3Kα and mTOR inhibitor that could influence cell proliferation and cycle of tumor cells. It was just...
AM-8508 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-8508 exhibits good cellular potency (in vitro pAKT IC50 = 4.6 nM ) and excellen...
AS-252424 is a novel, potent PI3Kγ inhibitor (IC50 of 30 nM) with a 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.
In the absence of PTEN phosphatase tumor suppressor function, PI3Kγ or PI3Kδ alone can support leukemogenesis, whereas inactivation of both isoforms suppressed ...
ETP-46321 is a potent and orally bioavailable PI3K α, δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after o...
PIK-93 is a potent PI3K inhibitor.